Street all-in on deposit surge and credit cost stability
With deposits and loans already in-hand (+29%, +32% YoY), the test on Oct 16 is whether credit costs stay benign and NIMs hold firm — management reset liability rates in Q2 to protect spreads.
The Setup: Deposit Firepower, but Can Margins Hold?
Ujjivan SFB walks into Q2 results with one hand full: deposits rose 29.2% YoY to ₹50,649 Cr and the loan book surged 32.1% to ₹45,699 Cr, both already disclosed in the Oct 3 business update. The question Oct 16 will answer is whether profit kept pace. Q1 delivered exceptional returns (PAT ₹317 Cr, +206.7% YoY) on a sharp dip in credit costs — the Street wants to see if that benign credit environment persists, or if Q2 credit cost normalizes upward. The other watch: with the bank actively resetting deposit rates across tenor buckets in Q2, did cost-of-funds compression offset any NIM squeeze? The interim CEO change (Carol Furtado took over Sep 1) adds a layer of execution risk, though the transition appears orderly.
~₹50.6k Cr
Oct 3 update: +29.2% YoY; CASA momentum visible
~₹45.7k Cr
Oct 3 update: +32.1% YoY; secured loans now 46.8% of book
~4.0–4.2%
Watch: cost-of-funds reset in Q2 vs. loan yield competition
₹80–110 Cr
Assume credit costs normalize from Q1's 30-bp exceptional run; net of higher CoF
A strong Q2: NIM contracts A weak Q2: Cost-of-funds benefit erodes vs. Q1 repricing lag; PAT <₹85 Cr; management flags CoF pressure into Q3.
On Track?
Ujjivan's FY27 RoA guidance stands at 1.8–2.0% (revised up from 1.6% post-Q1, Sep 1 filing). To hit the midpoint (1.9%), the bank needs steady PAT: Q1 ₹317 Cr was front-loaded on credit normalization, so Q2–Q4 needs average ₹90–110 Cr. Oct 3's deposit and loan growth numbers track the 25–30% AUM expansion implied in the FY27 guidance. The Street consensus estimates FY27 revenue at ₹4.90k Cr (+26.5% YoY) and EPS ₹5.40 (+53.9%). Q1 interest income grew 25.1% YoY — Q2 growth of 22–25% YoY would be in-line, a green flag.
What the Street Says
Since Last Quarter
Leadership: MD & CEO Sanjeev Nautiyal retired on health grounds; Carol Furtado, Executive Director, appointed Interim CEO effective Sep 1, 2026 (RBI-approved for 3 months). Vikas Agrawal joins as Business Head – MSME (effective Sep 1). No promoter pledges or FII exits flagged. Guidance: RoA raised to 1.8–2.0% from 1.6% (post-Q1, Jul 23). Investor actions: FII holding steady at 16.81% (Q1 FY27 vs. 17.23% in FY26 Q4); DII raised 233 bps to 33.45%. Marketing: New brand campaign ('Nothing Small About Us') launched Sep 18 with actor R. Madhavan. ESG: Upgraded to 82 (Outstanding) by ICRA (Aug 14); NSE rating 72 (Leader, Sep 2). Trading window closed Oct 1 for result season. No regulatory flags.
The Three Things to Watch Oct 16
1 · Credit Cost Normalization
Q1's 30-bp opex/credit cost run (and 206% profit surge) won't repeat. Watch PCR (provision coverage ratio) and slippage rates — do they stay <2.2%, or start trending toward 2.5%? A 5-bp PCR rise implies ₹15–20 Cr drag on profit.
2 · NIM Resilience
Cost-of-funds reset in Q2 was proactive (down 23 bps QoQ in Q2 FY26; expect similar). Did management lock in benefit, or did fresh deposit repricing eat it? Target: NIM <2 bps decline QoQ, else margin compression will concern bears.
3 · Carol Furtado's Messaging
First earnings call as Interim CEO; Street will listen for strategy continuity, OpEx/headcount outlook, and any interim-CEO caveats on 1.8–2.0% RoA guide. If guidance is reaffirmed and tone is steady, it's a green light; hesitation flags execution uncertainty.
Ujjivan SFB's Q2 result lands against a backdrop of explosive deposit and loan growth, a consensus all-in at Buy, and management's upgraded FY27 RoA target. The business engine is firing — now it's about proving credit costs stay low and NIMs don't compress. Oct 3's business update already set the tone: deposits and loans are in the bank; what matters Oct 16 is profit, margin, and the interim CEO's ability to sustain the arc. Expect a strong reaction if Q2 PAT tracks >₹100 Cr and management holds the 1.8–2.0% RoA band; a miss on either (or margin deterioration) will test the 17% upside in the consensus target.